158 related articles for article (PubMed ID: 28685624)
1. CXCR4 expression varies significantly among different subtypes of glioblastoma multiforme (GBM) and its low expression or hypermethylation might predict favorable overall survival.
Ma X; Shang F; Zhu W; Lin Q
Expert Rev Neurother; 2017 Sep; 17(9):941-946. PubMed ID: 28685624
[TBL] [Abstract][Full Text] [Related]
2. High EMP3 expression might independently predict poor overall survival in glioblastoma and its expression is related to DNA methylation.
Yue H; Xu Q; Xie S
Medicine (Baltimore); 2018 Jan; 97(1):e9538. PubMed ID: 29505529
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
Lehrer S; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
[TBL] [Abstract][Full Text] [Related]
4. Bioinformatic analyses reveal the key pathways and genes in the CXCR4 mediated mesenchymal subtype of glioblastoma.
Yi L; Tong L; Li T; Hai L; Abeysekera IR; Tao Z; Ma H; Liu P; Xie Y; Li J; Yuan F; Yu S; Yang X
Mol Med Rep; 2018 Jul; 18(1):741-748. PubMed ID: 29767255
[TBL] [Abstract][Full Text] [Related]
5. Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme.
Xia X; Cao F; Yuan X; Zhang Q; Chen W; Yu Y; Xiao H; Han C; Yao S
PeerJ; 2019; 7():e7974. PubMed ID: 31763067
[TBL] [Abstract][Full Text] [Related]
6. CDC6 is up-regulated and a poor prognostic signature in glioblastoma multiforme.
Zhao H; Zhou X; Yuan G; Hou Z; Sun H; Zhai N; Huang B; Li X
Clin Transl Oncol; 2021 Mar; 23(3):565-571. PubMed ID: 32661826
[TBL] [Abstract][Full Text] [Related]
7. SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients.
Feng Y; Wang Z; Bao Z; Yan W; You G; Wang Y; Hu H; Zhang W; Zhang Q; Jiang T
PLoS One; 2014; 9(3):e91829. PubMed ID: 24633048
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of TES by hypermethylation in glioblastoma reduces cell apoptosis and predicts poor clinical outcome.
Bai Y; Zhang QG; Wang XH
Eur J Med Res; 2014 Dec; 19(1):66. PubMed ID: 25498217
[TBL] [Abstract][Full Text] [Related]
9. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatic analysis of gene expression and methylation regulation in glioblastoma.
Wang W; Zhao Z; Wu F; Wang H; Wang J; Lan Q; Zhao J
J Neurooncol; 2018 Feb; 136(3):495-503. PubMed ID: 29168084
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
12. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
[TBL] [Abstract][Full Text] [Related]
13. miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma.
Shi Y; Chen C; Yu SZ; Liu Q; Rao J; Zhang HR; Xiao HL; Fu TW; Long H; He ZC; Zhou K; Yao XH; Cui YH; Zhang X; Ping YF; Bian XW
Clin Cancer Res; 2015 Sep; 21(17):4004-13. PubMed ID: 26023083
[TBL] [Abstract][Full Text] [Related]
14. Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns.
Ma H; Zhao C; Zhao Z; Hu L; Ye F; Wang H; Fang Z; Wu Y; Chen X
Cancer Gene Ther; 2020 Sep; 27(9):702-714. PubMed ID: 31619751
[TBL] [Abstract][Full Text] [Related]
15. A long non-coding RNA signature in glioblastoma multiforme predicts survival.
Zhang XQ; Sun S; Lam KF; Kiang KM; Pu JK; Ho AS; Lui WM; Fung CF; Wong TS; Leung GK
Neurobiol Dis; 2013 Oct; 58():123-31. PubMed ID: 23726844
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme.
Martinez R; Schackert G; Esteller M
J Neurooncol; 2007 Apr; 82(2):133-9. PubMed ID: 17048097
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic MSH6-CXCR4-TGFB1 Feedback Loop: A Novel Therapeutic Target of Photothermal Therapy in Glioblastoma Multiforme.
Chen Y; Liu P; Sun P; Jiang J; Zhu Y; Dong T; Cui Y; Tian Y; An T; Zhang J; Li Z; Yang X
Theranostics; 2019; 9(5):1453-1473. PubMed ID: 30867843
[TBL] [Abstract][Full Text] [Related]
18. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
19. Increased LGALS3 expression independently predicts shorter overall survival in patients with the proneural subtype of glioblastoma.
He X; Zhang S; Chen J; Li D
Cancer Med; 2019 May; 8(5):2031-2040. PubMed ID: 30848102
[TBL] [Abstract][Full Text] [Related]
20. The hedgehog antagonist HHIP as a favorable prognosticator in glioblastoma.
Chang L; Zhang P; Zhao D; Liu H; Wang Q; Li C; Du W; Liu X; Zhang H; Zhang Z; Jiang C
Tumour Biol; 2016 Mar; 37(3):3979-86. PubMed ID: 26482617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
